Diffuse Cutaneous Leishmaniasis Acquired in Peru
Eileen D. Franke, Carmen M. Lucas, Adolfo A. Tovar, J. Hever Kruger, Marisa Rivera, F. Stephen Wignall
Abstract
Eileen D. Franke, Carmen M. Lucas, Adolfo A. Tovar, J. Hever Kruger, Marisa Rivera, F. Stephen Wignall
Abstract
A case of diffuse cutaneous leishmaniasis (DCL) acquired in Peru is described. The causative agent was Leishmania mexicana amazonensis as determined by isoenzyme analysis and species-specific monoclonal antibody binding characteristics. Histological examination of biopsy material showed a large number of intracellular and extracellular amastigotes and few lymphocytes. Treatment with meglumine antimoniate (Glucantime) administered iv at a dosage of 20 mg antimony/kg body weight/day for 60 days resulted in visible improvement of the lesions, but not in clinical or parasitological cure.
OpenAlex reports 18 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
A case of diffuse cutaneous leishmaniasis (DCL) acquired in Peru is described. The causative agent was Leishmania mexicana amazonensis as determined by isoenzyme analysis and species-specific monoclonal antibody binding characteristics. Histological examination of biopsy material showed a large number of intracellular and extracellular amastigotes and few lymphocytes. Treatment with meglumine antimoniate (Glucantime) administered iv at a dosage of 20 mg antimony/kg body weight/day for 60 days resulted in visible improvement of the lesions, but not in clinical or parasitological cure.
Key concepts: Meglumine antimoniate, Cutaneous leishmaniasis, Leishmaniasis, Leishmania, Monoclonal antibody, Amastigote, Protozoal disease, Medicine